1-2 of 2
Jeremy Ryan
Close
Sort by
Journal Articles

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Clinical Trials & Observations
Jacqueline S. Garcia, Haesook T. Kim, H. Moses Murdock, Michela Ansuinelli, Jennifer Brock, Corey S. Cutler, Mahasweta Gooptu, Vincent T. Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman Shapiro, Daniel J. DeAngelo, Richard M. Stone, Denbaa Bat-Erdene, Jeremy Ryan, Manuel E. Contreras, Geoffrey Fell, Anthony Letai, Jerome Ritz, R. Coleman Lindsley, Robert J. Soiffer, Joseph H. Antin
Journal: Blood Advances
Blood Adv (2024) 8 (4): 978–990.
https://doi.org/10.1182/bloodadvances.2023012120
Published: 2024
Includes: Supplemental data
Journal Articles

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Clinical Trials & Observations
Jacqueline S. Garcia, Haesook T. Kim, H. Moses Murdock, Corey S. Cutler, Jennifer Brock, Mahasweta Gooptu, Vincent T. Ho, John Koreth, Sarah Nikiforow, Rizwan Romee, Roman Shapiro, Fiona Loschi, Jeremy Ryan, Geoffrey Fell, Hannah Q. Karp, Fabienne Lucas, Annette S. Kim, Danielle Potter, Thelma Mashaka, Richard M. Stone, Daniel J. DeAngelo, Anthony Letai, R. Coleman Lindsley, Robert J. Soiffer, Joseph H. Antin
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5536–5545.
https://doi.org/10.1182/bloodadvances.2021005566
Published: 2021
Includes: Supplemental data